Lexicon Pharmaceuticals | LXRX - Pre Tax Profit


Lexicon Pharmaceuticals reported $-12.77M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
Abbott USD 2.39B 27M Mar/2026
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Akebia Therapeutics USD -11.24M 12.39M Dec/2025
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
AstraZeneca USD 3.91B 1.28B Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Halozyme Therapeutics USD 180.33M 281.18M Mar/2026
Illumina USD 157M 220M Mar/2026
Insmed USD -162.1M 164.84M Mar/2026
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
J&J USD 7.82B 2.86B Mar/2026
Lexicon Pharmaceuticals USD -12.77M 16.02M Sep/2025
MacroGenics USD -14.93M 31.75M Dec/2025
MannKind USD -16.37M 4.56M Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Moderna USD -799M 612M Dec/2025
Novartis USD 3.84B 802M Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Thermo Fisher Scientific USD 2.12B 295M Dec/2025
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
United Therapeutics USD 444M 6M Dec/2025
Vanda Pharmaceuticals USD -22.92M 16.68M Dec/2024